Crossover Comparison of Efficacy and Preference
for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine
by
Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M.
Ottawa Headache Centre, Ottawa, Canada.
Eur Neurol 2003;49(1):20-9

ABSTRACT

Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p /=5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).

TCAs
SSRIs
5-HTP
Triptans
Migraine
Sumatriptan
Zolmitriptan
Moclobemide
Beta-blockers
Antidepressants
Rizatriptan (Maxalt)
Migraine prophylaxis
Venlafaxine/headaches
Triptans, migraine and depression

Refs
and further reading

HOME
HedWeb
Nootropics
Cocaine.org
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family